Empagliflozin attenuates neointimal hyperplasia after drug-eluting-stent implantation in patients with type 2 diabetes

How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial

(2019) Agnes Bosch et al.   Cardiovascular Diabetology

Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects

(2019) Motoaki Sano et al.   CIRCULATION

Luseogliflozin attenuates neointimal hyperplasia after wire injury in high-fat diet-fed mice via inhibition of perivascular adipose tissue remodeling

(2019) Yusaku Mori et al.   Cardiovascular Diabetology

Empagliflozin's Ameliorating Effect on Plasma Triglycerides: Association with Endothelial Function Recovery in Diabetic Patients with Coronary Artery Disease

(2019) Takahiro Sawada et al.   Journal of Atherosclerosis and Thrombosis

Cardiovascular Effects of New Oral Glucose-Lowering Agents

(2018) André J. Scheen   CIRCULATION RESEARCH

Switching dipeptidyl peptidase-4 inhibitors to tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2 improves arterial stiffness evaluated by cardio-ankle vascular index in patients with type 2 diabetes

(2018) Nobuhiro Tahara et al.   Current Vascular Pharmacology

2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults

(2018) Paul K. Whelton et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Comparative assessment of three drug eluting stents with different platforms but with the same biodegradable polymer and the drug based on quantitative coronary angiography and optical coherence tomography at 12-month follow-up

(2017) Robert J. Gil et al.   INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING

Characteristics of early versus late in-stent restenosis in second-generation drug-eluting stents: an optical coherence tomography study

(2017) Lei Song et al.   EuroIntervention

2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery

(2016) Glenn N. Levine et al.   CIRCULATION

Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors

(2016) Takamasa Ohki et al.   CLINICAL DRUG INVESTIGATION

The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE −/− mice fed a western diet

(2016) Ji Hye Han et al.   DIABETOLOGIA

Mechanisms of stent thrombosis analysed by optical coherence tomography: insights from the national PESTO French registry

(2016) Geraud Souteyrand et al.   EUROPEAN HEART JOURNAL

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial

(2016) David Fitchett et al.   EUROPEAN HEART JOURNAL

Impact of the 8-week Administration of Tofogliflozin for Glycemic Control and Body Composition in Japanese Patients with Type 2 Diabetes Mellitus

(2016) Sachie Hirose et al.   INTERNAL MEDICINE

The Ultimaster Biodegradable-Polymer Sirolimus-Eluting Stent: An Updated Review of Clinical Evidence

(2016) Alberto Chisari et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

(2016) Christoph Wanner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Randomized Trial of Intensive versus Standard Blood-Pressure Control

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

Roles of Bone-Marrow-Derived Cells and Inflammatory Cytokines in Neointimal Hyperplasia after Vascular Injury

(2014) Makoto Shoji et al.   Biomed Research International

Correlation Between Degree of Neointimal Hyperplasia and Incidence and Characteristics of Neoatherosclerosis as Assessed by Optical Coherence Tomography

(2013) Rocco Vergallo et al.   AMERICAN JOURNAL OF CARDIOLOGY

Primary Endpoint Results of the EVOLVE Trial

(2012) Ian T. Meredith et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Consensus Standards for Acquisition, Measurement, and Reporting of Intravascular Optical Coherence Tomography Studies

(2012) Guillermo J. Tearney et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: comparison with sirolimus-eluting stents

(2009) J-S Kim et al.   HEART

Effects of Intensive Glucose Lowering in Type 2 Diabetes

(2008)   NEW ENGLAND JOURNAL OF MEDICINE